2017
Predictors of Waitlist Mortality in Portopulmonary Hypertension
DuBrock HM, Goldberg DS, Sussman NL, Bartolome SD, Kadry Z, Salgia RJ, Mulligan DC, Kremers WK, Kawut SM, Krowka MJ, Channick RN. Predictors of Waitlist Mortality in Portopulmonary Hypertension. Transplantation 2017, 101: 1609-1615. PMID: 28207639, PMCID: PMC5481480, DOI: 10.1097/tp.0000000000001666.Peer-Reviewed Original ResearchMeSH KeywordsArterial PressureCause of DeathChi-Square DistributionDatabases, FactualDecision Support TechniquesFemaleHumansHypertension, PortalHypertension, PulmonaryKaplan-Meier EstimateLiver DiseasesLiver TransplantationMaleMiddle AgedMultivariate AnalysisPortal PressurePredictive Value of TestsProportional Hazards ModelsPulmonary ArteryPulmonary CirculationRetrospective StudiesRisk AssessmentRisk FactorsSeverity of Illness IndexTime FactorsTissue and Organ ProcurementTreatment OutcomeVascular ResistanceWaiting ListsConceptsPortopulmonary hypertensionWaitlist mortalityMELD exceptionsLiver diseaseException scoreEnd-Stage Liver Disease (MELD) exception pointsSignificant predictorsCox proportional hazards modelMELD exception scoreWaitlist mortality riskRetrospective cohort studyPulmonary arterial pressureTransplantation Network databaseSignificant univariate predictorsOnly significant univariate predictorsProportional hazards modelMELD scorePosttransplant mortalityPulmonary hypertensionCohort studyArterial pressureUnivariate predictorsC-statisticMortality riskHazards model
2011
A randomized, multicenter study comparing steroid‐free immunosuppression and standard immunosuppression for liver transplant recipients with chronic hepatitis C
Klintmalm GB, Davis GL, Teperman L, Netto GJ, Washburn K, Rudich SM, Pomfret EA, Vargas HE, Brown R, Eckhoff D, Pruett TL, Roberts J, Mulligan DC, Charlton MR, Heffron TG, Ham JM, Douglas DD, Sher L, Baliga PK, Kinkhabwala M, Koneru B, Abecassis M, Millis M, Jennings LW, Fasola CG. A randomized, multicenter study comparing steroid‐free immunosuppression and standard immunosuppression for liver transplant recipients with chronic hepatitis C. Liver Transplantation 2011, 17: 1394-1403. PMID: 21850690, DOI: 10.1002/lt.22417.Peer-Reviewed Original ResearchMeSH KeywordsAdrenal Cortex HormonesAntibodies, Monoclonal, HumanizedAntiviral AgentsBiopsyChi-Square DistributionDaclizumabDrug Therapy, CombinationFemaleGraft RejectionHepacivirusHepatitis C, ChronicHumansImmunoglobulin GImmunosuppressive AgentsKaplan-Meier EstimateLiver FailureLiver TransplantationMaleMiddle AgedMycophenolic AcidProportional Hazards ModelsProspective StudiesRecurrenceRisk AssessmentRisk FactorsRNA, ViralSurvival RateTacrolimusTime FactorsTreatment OutcomeUnited StatesConceptsAcute cellular rejectionSteroid-free immunosuppressionLiver transplant recipientsHCV recurrenceMycophenolate mofetilTransplant recipientsHCV RNA-positive subjectsHepatitis C virus infectionSevere HCV recurrenceSteroid-free groupC virus infectionChronic hepatitis CGraft survival ratesProportion of patientsLiver biopsy samplesCellular rejectionChronic HCVStandard immunosuppressionSteroid sparingHepatitis CLess diabetesMulticenter trialMulticenter studyPatient survivalArm 1
2010
Hepatic epithelioid haemangioendothelioma: is transplantation the only treatment option?
Grotz TE, Nagorney D, Donohue J, Que F, Kendrick M, Farnell M, Harmsen S, Mulligan D, Nguyen J, Rosen C, Reid-Lombardo K. Hepatic epithelioid haemangioendothelioma: is transplantation the only treatment option? Hepato Pancreato Biliary 2010, 12: 546-553. PMID: 20887322, PMCID: PMC2997660, DOI: 10.1111/j.1477-2574.2010.00213.x.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedAntineoplastic AgentsChi-Square DistributionDisease-Free SurvivalFemaleHemangioendothelioma, EpithelioidHepatectomyHumansKaplan-Meier EstimateLiver NeoplasmsLiver TransplantationMaleMiddle AgedPalliative CareProportional Hazards ModelsRetrospective StudiesRisk AssessmentRisk FactorsSurvival RateTime FactorsTreatment OutcomeUnited StatesYoung AdultConceptsHepatic epithelioid haemangioendotheliomaOrthotopic liver transplantationDisease-free survivalLiver resectionOverall survivalPrognostic factorsFavorable prognostic factorUnfavourable prognostic factorOnly treatment optionUnpredictable clinical behaviorRare vascular neoplasmResectable diseaseUnresectable diseaseEpithelioid haemangioendotheliomaLiver transplantationFavorable OSFemale predominanceMedian ageSurgical treatmentMultifocal diseaseRetrospective reviewTreatment optionsLarge tumorsClinical behaviorMayo ClinicRelationship between Inpatient Hyperglycemia and Insulin Treatment after Kidney Transplantation and Future New Onset Diabetes Mellitus
Chakkera HA, Knowler WC, Devarapalli Y, Weil EJ, Heilman RL, Dueck A, Mulligan DC, Reddy KS, Moss AA, Mekeel KL, Mazur MJ, Hamawi K, Castro JC, Cook CB. Relationship between Inpatient Hyperglycemia and Insulin Treatment after Kidney Transplantation and Future New Onset Diabetes Mellitus. Clinical Journal Of The American Society Of Nephrology 2010, 5: 1669-1675. PMID: 20558559, PMCID: PMC2974410, DOI: 10.2215/cjn.09481209.Peer-Reviewed Original ResearchConceptsKidney transplant recipientsInpatient hyperglycemiaKidney transplantationTransplant recipientsInsulin therapyNondiabetic kidney transplant recipientsDevelopment of NODATRisk of NODATNew-onset diabetesKidney transplant surgeryCapillary blood glucoseNondiabetic patientsYear posttransplantCardiovascular eventsNew onsetDiabetes mellitusMedical therapyAdjusted analysisStudy cohortRetrospective studyTransplant surgeryBlood glucoseSerum glucoseInsulin treatmentNODAT
2009
Natural history of post–liver transplantation hepatitis C: A review of factors that may influence its course
Gallegos‐Orozco J, Yosephy A, Noble B, Aqel BA, Byrne TJ, Carey EJ, Douglas DD, Mulligan D, Moss A, de Petris G, Williams JW, Rakela J, Vargas HE. Natural history of post–liver transplantation hepatitis C: A review of factors that may influence its course. Liver Transplantation 2009, 15: 1872-1881. PMID: 19938138, DOI: 10.1002/lt.21954.Peer-Reviewed Original ResearchMeSH KeywordsAcute DiseaseAdultBiopsyDisease ProgressionFemaleGraft RejectionHepatitis CHumansKaplan-Meier EstimateLiver CirrhosisLiver FailureLiver TransplantationLiving DonorsMaleMiddle AgedProportional Hazards ModelsRecurrenceRetrospective StudiesRisk AssessmentRisk FactorsSeverity of Illness IndexTime FactorsTreatment OutcomeConceptsEnd-stage liver diseaseHCV-positive recipientsLiver transplantHepatocellular carcinomaHCV recurrenceAcute rejectionPatient survivalBiopsy-proven acute rejectionMedian age 53 yearsHistory of HCCAggressive HCV recurrenceEarly acute rejectionProtocol liver biopsiesSignificant HCV recurrenceAdult liver transplantsAdvanced donor ageAge 53 yearsAge 39 yearsDay of transplantationLong-term survivalElectronic medical recordsAvoidance of rejectionEvaluable populationRapid fibrosersHepatitis C
2006
Liver Transplantation in the MELD Era: A Single-Center Experience
Sachdev M, Hernandez JL, Sharma P, Douglas DD, Byrne T, Harrison ME, Mulligan D, Moss A, Reddy K, Vargas HE, Rakela J, Balan V. Liver Transplantation in the MELD Era: A Single-Center Experience. Digestive Diseases And Sciences 2006, 51: 1070-1078. PMID: 16865573, DOI: 10.1007/s10620-006-8011-1.Peer-Reviewed Original ResearchMeSH KeywordsArizonaCarcinoma, HepatocellularFemaleHepatitis CHumansLiver DiseasesLiver NeoplasmsLiver TransplantationMaleMedical RecordsMiddle AgedOutcome Assessment, Health CareResource AllocationRetrospective StudiesRisk AssessmentSeverity of Illness IndexSurvival AnalysisTissue and Organ ProcurementWaiting ListsConceptsDeceased donor liver transplantationLiver transplantationTransplantation ratesEndstage Liver Disease (MELD) scoreImpact of MELDDonor liver transplantationLiver Disease scoreUnderlying liver diseaseSingle-center experienceHepatocellular carcinoma patientsHepatitis C virusNew allocation policyHCC candidatesMELD implementationNew MELDTimely transplantClinical deteriorationMELD eraCarcinoma patientsLiver diseaseHepatitis C virus groupC virusHCC patientsMayo ClinicDropout rate